Key result
Routine genetic testing and MRI screening to withhold warfarin therapy did not improve outcomes for average-risk patients unless the relative hazard of intracerebral hemorrhage exceeded 23.8.
Why the study?
Do screening strategies including genetic profiling and neuroimaging improve the safety of chronic anticoagulation for atrial fibrillation by identifying individuals from whom warfarin should be withheld?
Do screening strategies including genetic profiling and neuroimaging improve the safety of chronic anticoagulation for atrial fibrillation by identifying individuals from whom warfarin should be withheld?
Routine genetic testing and MRI screening for bleeding risk do not currently improve outcomes enough to justify withholding warfarin in average-risk patients with nonvalvular atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Does not support routine genetic testing or MRI screening to withhold warfarin in average-risk AF; leaves open benefit only if ICH hazard exceeds 23.8.
Eckman et al. (2008) studied Nonvalvular atrial fibrillation. Genetic profiling and MRI screening vs. Routine anticoagulation (warfarin) was evaluated on Quality-adjusted life-years. Routine genetic testing and MRI screening to withhold warfarin therapy did not improve outcomes for average-risk patients unless the relative hazard of intracerebral hemorrhage exceeded 23.8.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: